Our Product : Tiprelestat is a game changing innovation
Tiprelestat is a pioneering anti-inflammatory and tissue protective drug being developed for the treatment of pulmonary arterial hypertension (PAH) and other potential indications, such as the early treatment of postoperative inflammatory complications.
Our Vision : Natural protection smart reinvented
We at tiakis develop novel and groundbreaking therapeutic solutions in indications with high unmet medical need.
Our drive is to make use of the human body’s own defense mechanisms to protect against tissue damage and inflammation driven complications.
Our investigational medicinal product, Tiprelestat, is being developed as a driver of a paradigm change, a therapeutic solution and long-term treatment of pulmonary arterial hypertension (PAH). Tiprelestat is specifically designed to target pulmonary vascular remodeling and inflammation of this debilitating and rapidly progressive rare disease with high unmet medical need.
Mechanism of action : Tiprelestat – the tissue protective agent
Tiprelestat is identical to the human protein elafin and a potent reversible inhibitor of human neutrophil elastase and proteinase 3. It’s able to inhibit their activity almost completely in vitro and in vivo.
Tiprelestat is associated with a significantly reduced postoperative need for intensive care in patients undergoing esophageal cancer surgery.
Tiprelestat inhibits the formation of neutrophil exosomes and neutrophil extracellular traps, inhibits NFkB and restores pathologic bone morphogenic protein signaling.
Tiprelestat reduces, in vivo, vascular smooth muscle cell proliferation and vascular occlusion and promotes alveolar formation.
Tiprelestat suppresses reperfusion injury occurring after heart transplantation, myocardial infarction, and skeletal muscle ischemia.
Tiprelestat is able to revert the pathology in pulmonary arterial hypertension and to reduce ventilator induced injury.
Tiprelestat is well tolerated and has been subjected to numerous preclinical and clinical investigations in a variety of disease areas.
In-focus medical fields Tiprelestat
Good reasons for Tiprelestat
Excellent safety profile of Tiprelestat was demonstrated in five randomized, placebo controlled clinical trials (n=109).
Granted orphan designation in the US and EU for the treatment of patients with PAH and biologics exclusivity in the US.
We will gladly answer your questions.
Get in Contact
phone: +49 431 8888 462
email: info@tiakis.bio